| Jul 31,
2018 | Jul 31,
2019 | Jul 31,
2020 | Jul 31,
2021 | Jul 31,
2022 | Jul 31,
2023 | Jul 31,
2024 |
|---|
| Infusion Technology | - | - | - | - | - | - | 0 |
|---|
| Rental – Third Party | - | - | - | - | - | 0 | 0 |
|---|
| Rental – Related Party | - | - | - | - | - | 0 | 0 |
|---|
| Total revenue | 4 | 5 | 5 | 4 | 0 | 0 | 1 |
|---|
| Cost of Infusion Technology revenue | - | - | - | - | - | - | 0 |
|---|
| General and administrative | - | - | - | - | - | 9 | 9 |
|---|
| Research and development | 1 | 1 | 2 | 5 | 9 | 6 | 4 |
|---|
| In-process research and development expense | - | - | - | - | - | - | 90 |
|---|
| Depreciation and amortization | 2 | 2 | 2 | 1 | 0 | 0 | 0 |
|---|
| Loss from operations | -4 | -7 | -8 | -30 | -60 | -15 | -103 |
|---|
| Interest income | - | - | - | - | 0 | 3 | 2 |
|---|
| Impairment of investments - Other Pharmaceuticals | - | - | - | - | 79 | - | - |
|---|
| Loss on initial investment in Day Three upon acquisition | - | - | - | - | - | - | 2 |
|---|
| Realized gain on available-for-sale securities | - | - | - | - | - | - | 2 |
|---|
| Realized gain (loss) on investment in equity securities | - | - | - | - | - | 0 | -0 |
|---|
| Unrealized gain on investment in equity securities | - | - | - | - | - | 0 | - |
|---|
| Realized gain on investment - Cyclo | - | - | - | - | - | - | 0 |
|---|
| Unrealized gain on investment - Cyclo | - | - | - | - | - | - | 0 |
|---|
| Unrealized gain on convertible notes receivable, due from Cyclo | - | - | - | - | - | - | 1 |
|---|
| Unrealized gain on investment - Hedge Funds | - | - | - | - | - | - | 0 |
|---|
| Recovery of receivables from Cornerstone | - | - | - | - | - | - | 31 |
|---|
| Interest expense | - | - | - | - | 0 | - | 0 |
|---|
| Other income | - | - | - | - | - | - | 0 |
|---|
| Loss from continuing operations before income taxes | -4 | -5 | -7 | -25 | -140 | -9 | -67 |
|---|
| Benefit from income taxes | 8 | -0 | 0 | 0 | - | -0 | -3 |
|---|
| Equity in loss of Day Three | - | - | - | - | - | - | 0 |
|---|
| Consolidated net loss from continuing operations | - | - | - | - | -141 | -9 | -65 |
|---|
| Loss from discontinued operations related to 520 Property | - | - | - | - | - | -0 | - |
|---|
| Gain on disposal of 520 Property | - | - | - | - | -2 | 7 | - |
|---|
| Income from discontinued operations | - | - | - | - | -2 | 6 | - |
|---|
| Consolidated net loss | -12 | -5 | -11 | - | -142 | -2 | -65 |
|---|
| Net loss attributable to noncontrolling interests | -0 | -0 | -0 | - | -18 | -0 | -31 |
|---|
| Net loss attributable to Rafael Holdings, Inc. | -12 | -5 | -10 | -25 | -141 | -2 | -34 |
|---|
| Consolidated net loss | -12 | -5 | -11 | - | -142 | -2 | -65 |
|---|
| Unrealized (loss) gain on available-for-sale securities | - | - | - | - | - | -0 | 0 |
|---|
| Foreign currency translation adjustment | - | - | - | - | 0 | - | 0 |
|---|
| Comprehensive loss | - | -5 | -11 | - | - | -3 | -65 |
|---|
| Comprehensive loss attributable to noncontrolling interests | - | - | - | - | - | - | -31 |
|---|
| Comprehensive loss attributable to Rafael Holdings, Inc. | - | -4 | -11 | -25 | -125 | -2 | -34 |
|---|
| Continuing operations basic (in Dollars per share) | - | - | - | - | -6.22 | -0.36 | -1.45 |
|---|
| Continuing operations diluted (in Dollars per share) | - | - | - | - | - | - | -1.45 |
|---|
| Discontinued operations basic (in Dollars per share) | - | - | - | - | -0.09 | 0.28 | - |
|---|
| Total basic loss per share (in Dollars per share) | -0.93 | - | - | - | -6.31 | -0.08 | -1.45 |
|---|
| Total diluted loss per share (in Dollars per share) | -0.93 | - | - | - | -6.31 | -0.08 | -1.45 |
|---|